NASP 2025 Annual Meeting & Expo: Location, Dates, What to Expect, and What’s Happeninghttps://shieldshealthsolutions.com/content/themes/blade/images/empty/thumbnail.jpg150150Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Each year, NASP members, industry thought leaders, and healthcare veterans from around the country come together to shape the future of specialty pharmacy and the patient journey. Join us to…
Artificial Intelligence in Specialty Pharmacy: Innovation That Empowers, Not Replaceshttps://shieldshealthsolutions.com/content/uploads/2024/11/blog.svg7070Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Will AI replace pharmacists and technicians? It’s a question that has sparked both curiosity and concern across the healthcare landscape, and understandably so, as artificial intelligence (AI) has already had…
Ambulatory Clinical Pharmacist Impact on Coverage Outcomes for Specialty Oncology Medicationshttps://shieldshealthsolutions.com/content/uploads/2023/05/web-resources-icon-posters.png216115Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
This poster evaluates the cimpact of an ACP program on third party pharmacy coverage determination outcomes for specialty oncology medications prescribed from these clinics.
Clinical, Safety, and Quality Outcomes of a Hypertrophic Cardiomyopathy Clinical Pharmacy Management Programhttps://shieldshealthsolutions.com/content/uploads/2023/05/web-resources-icon-posters.png216115Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
This poster evaluates the clinical, safety, and quality outcomes of a pharmacist-led HCM clinical management program.
Analysis of Oral Oncolytic Waste for Patients Filling at a Health System Specialty Pharmacyhttps://shieldshealthsolutions.com/content/uploads/2023/05/web-resources-icon-posters.png216115Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
This poster evaluates existing oral oncology medication waste events among patients filling at a HSSP.
Unlocking the Full Potential of Your DIY Specialty Pharmacy Program: Why Strategic Partnership Mattershttps://shieldshealthsolutions.com/content/uploads/2024/11/blog.svg7070Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Specialty pharmacy is one of the fastest-growing and most essential parts of today’s healthcare landscape — and you’re likely already feeling both the opportunity and the pressure. As the number…
How CHRISTUS Health Reimagined Diabetes Support Through Health System Specialty Pharmacyhttps://shieldshealthsolutions.com/content/uploads/2024/11/case-studies.svg7070Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
This white paper explores the opportunities and unknowns that health organizations must consider when weighing the implementation of AI.
Shields Health Solutions Partners with Major Academic Medical Center to Expand Specialty Pharmacy Serviceshttps://shieldshealthsolutions.com/content/uploads/2021/06/shields-blog-icon-pr-1.svg204115Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
STOUGHTON, Mass. (May 13, 2025)–Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country announced it has partnered with Duke Health, a leading academic health system in North…
Analysis of Glucagon-Like Peptide-1 Agonist Trends Within An Integrated Health System Specialty Pharmacyhttps://shieldshealthsolutions.com/content/uploads/2024/11/white-papers.svg7070Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
According to the CDC, approximately 38 million Americans have diabetes (about 1 in 10) and approximately 90-95% of those have type 2 diabetes. GLP-1 and GLP-1/GIP agonists are now recognized…
Addressing GLP-1 Access and Adherence Challenges with Specialty Pharmacy Solutionshttps://shieldshealthsolutions.com/content/uploads/2024/11/blog.svg7070Shields Health SolutionsShields Health Solutions//shieldshealthsolutions.com/content/uploads/2021/05/shields-logo-white.svg
Whether through social media, traditional news outlets, or word of mouth, discussions about GLP-1 therapy are everywhere. These medications, originally approved by the FDA for the treatment of Type 2…